ClinicalTrials.gg

Program

pridopidine

Also written as “Pridopidine”, “ACR16” and “pridopidine (90 mg)”.

Its studies are mostly in Huntington Disease · Amyotrophic Lateral Sclerosis · Parkinson Disease, led by 2 companies.

Furthest: phase 3, since Sep 14, 202010 company-led studies, 2 open or runningNext primary completion: Mar 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Prilenia82 open or runningphase 3since Sep 14, 2020Feb 28, 2011Mar 2028phase 3 · NCT07322003
Teva Pharmaceutical Industries20 open or runningphase 3since Apr 22, 2008Apr 22, 2008none ahead

Also a collaborator on its studies: Ferrer Internacional.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 22, 2008First study: phase 3 study in Huntington DiseaseNew to Teva Pharmaceutical IndustriesTeva Pharmaceutical Industries · NCT00665223 · 437 enrolled · Austria, Belgium, France and more
  2. Jul 24, 2008Phase 2 study in Huntington DiseaseTeva Pharmaceutical Industries · NCT00724048 · 227 enrolled · United States, Canada
  3. Feb 28, 2011Prilenia's first study: phase 2 study in Huntington DiseaseNew to PrileniaPrilenia · NCT01306929 · 134 enrolled
  4. Dec 5, 2013Phase 2 study in Huntington DiseasePrilenia · NCT02006472 · 408 enrolled · United States, Australia, Austria and more
  5. Jul 7, 2015Phase 2 study in Huntington DiseasePrilenia · NCT02494778 · 248 enrolled · United States, Australia, Austria and more
  6. Jan 3, 2017Phase 1 study in Huntington DiseasePrilenia · NCT03019289 · 23 enrolled · Germany
  7. Apr 17, 2019Phase 2 study in Parkinson DiseasePrilenia · NCT03922711 · 23 enrolled · United States
  8. Sep 14, 2020Phase 3 study in Huntington DiseasePrilenia · NCT04556656 · 499 enrolled · United States, Austria, Canada and more
  9. Jan 5, 2026Phase 3 study in Amyotrophic Lateral SclerosisPrilenia · NCT07322003 · 500 planned · United States, Belgium, Canada and more
  10. May 20, 2026Phase 3 study in Huntington DiseasePrilenia · NCT07609108 · 400 planned · United States, Belgium, Canada and more

Ahead

  1. Mar 2028Primary completion: phase 3 study in Amyotrophic Lateral SclerosisPrilenia · NCT07322003
  2. Jun 2028Primary completion: phase 3 study in Huntington DiseasePrilenia · NCT07609108

TargetBeta

DRD2 →read by rule
“Dopamine D2 receptor modulator”ChEMBL 37, by rule

Other programs on DRD2

ProgramCompanyFurthest phaseStudies
AripiprazoleruleOtsukaphase 4131
RisperidoneruleJohnson & Johnsonphase 4111
paliperidoneruleJohnson & Johnsonphase 4106
OlanzapineruleEli Lillyphase 476
brexpiprazoleruleOtsukaphase 470
rotigotineruleUCBphase 464
lurasidoneruleSumitomo Pharmaphase 452
PramipexoleruleBoehringer Ingelheimphase 444
iloperidoneruleVanda Pharmaceuticalsphase 415
CabergolineruleChangchun GeneScience Pharmaceuticalphase 48
cariprazineruleAbbViephase 341
lumateperoneruleJohnson & Johnsonphase 325

Studies

All 10 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07609108Huntington Disease · United States, Belgium, Canada and more3RecruitingPrileniaJun 2028400
NCT07322003Amyotrophic Lateral Sclerosis · United States, Belgium, Canada and more3RecruitingPrileniaMar 2028500
NCT04556656Huntington Disease · United States, Austria, Canada and more3CompletedPrileniaMar 14, 2023499
NCT03922711Parkinson Disease · United States2TerminatedPrileniaJul 22, 202023
NCT03019289Huntington Disease · Germany1CompletedPrileniaFeb 9, 201823
NCT02494778Huntington Disease · United States, Australia, Austria and more2TerminatedPrileniaJan 12, 2018248
NCT02006472Huntington Disease · United States, Australia, Austria and more2CompletedPrileniaDec 16, 2015408
NCT01306929Huntington Disease2CompletedPrileniaJan 5, 2018134
NCT00724048Huntington Disease · United States, Canada2CompletedTeva Pharmaceutical IndustriesJul 26, 2010227
NCT00665223Huntington Disease · Austria, Belgium, France and more3CompletedTeva Pharmaceutical IndustriesJun 14, 2010437

How it is read

Names in the registry

  • “Pridopidine”, 6 entries
  • “ACR16”, 2 entries
  • “pridopidine”, 1 entry
  • “pridopidine (90 mg)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.